Inhalation product capabilities and in-house technologies including:
Particle Engineering
- Micronisation
- Spray Drying
Blending Technologies
- Low-shear mixing (Turbula)
- High-shear mixing (PMA, TRV)
Capsule Filling
- Xcelodose® 600s
- 3P R1000
- Harro Hofliger Modu-C LS
Analytical Support
- HPLC & UPLC
- Particle size distribution (laser diffraction)
- NGI, ED/DDU
- Malvern Spraytec
- Solid-state analysis: XRPD, DSC, STA, DVS
Precision inhaled drug development for better patient outcomes.
We tailor each strategy to the attributes of your molecule and therapeutic goals, supporting effective lung delivery and patient-centric outcomes.
Dry Powder Inhalers (DPIs) Development
Success in the development of dry powder inhalers, or DPIs, starts with a deep understanding of the API’s physical properties – yet few compounds are naturally ideal for inhalation.
We apply advanced particle engineering techniques, such as micronisation with carrier blending or spray-dried dispersion, to optimize aerosol performance.
Nebuliser Development
Nebulisers are ideal for delivering large volumes of low-dose medication or supporting patients who find inhalers challenging to use.
Our formulation scientists develop optimized droplet and delivery systems to – ensuring reliable, targeted delivery and therapeutic performance.
Nasal Spray Development
Nasal delivery offers fast systemic absorption and, uniquely, direct access to the brain – opening new avenues for therapies targeting the central nervous system.
We match the formulation to your molecule’s characteristics to maximize bioavailability, patient compliance, and therapeutic impact.
